BioSpace News Archive

Myomo, Inc., a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced the launch of MyoCare™, a new program that provides enhanced support to first-year users of the Company’s MyoPro® powered brace in order to maximize the benefits they receive from the device.

Centogene N.V., a commercial-stage diagnostics and genetic research company, announced that its paper ‘Rapid Large-Scale COVID-19 Testing During Shortages’ has been published in Diagnostics, an international peer-reviewed open access journal on medical diagnosis.

Mylan N.V. and Fujifilm Kyowa Kirin Biologics Co., Ltd. announced that the U.S. Food and Drug Administration has approved Hulio®, a biosimilar to AbbVie’s Humira®, for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis, in both prefilled syringe and auto-injector presentations.

AIM ImmunoTech, announced that it has entered into a clinical trial agreement with Roswell Park Comprehensive Cancer Center to support Roswell Park’s Phase 1/2a trial of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19, the disease caused by the SARS-CoV-2 coronavirus.

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration has accepted and granted priority review for a new supplemental Biologics License Application for KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

Orchard Therapeutics, a global gene therapy leader, and MolMed S.p.A, one of the company’s principal contract development and manufacturing partners, announced that they have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025.

Company providing BXCL501 to evaluate its activity in patients with COVID-19 that may require calming or arousable sedation following intubation

Dr. William Andrews brings two decades of global industry experience, including more than 13 years in rare diseases and seven product launches

Finerenone reduced the combined primary endpoint of risk of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care

BRILINTA in combination with aspirin could be the first FDA-approved dual antiplatelet therapy to reduce the rate of stroke in these high-risk patients